Novartis AG
NVS
|
$84.17
-1.3%
0.17%
|
|
Health Technology
(0.0% 1d) (-7.0% 1m) (-7.7% 1y) (0.0% 2d) (-1.3% 3d) (3.2% 7d) (-26.32% volume)
Earnings Calendar:
http://www.novartis.com
Sec Filling | Patents | 103914 employees
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
add to watch list email alert is off
Price chart
% (High / Open) change chart
Press-releases
Cancer Immunotherapy Market Expands with Rising Adoption of Target Therapy in Cancer Treatment, States TMR Report
Published: 2022-06-27 (Crawled : 16:00) - prnewswire.com
AZNCF | $127.2501 |
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
LLY | News S | $317.62 -2.95% -0.03% |
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
GSK | $43.35 -0.8% 0.19% |
|
Health Technology
|
| O: -0.16%
H: 0.61%
C: 0.18%
GLAXF | $21.99 |
|
Health Technology
|
| O: 0.47%
H: 3.73%
C: 3.73%
PFE | News | $50.66 -2.35% 0.4% |
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
SPPI A | $0.8436 -1.91% 1.74% |
|
Health Technology
|
| O: 0.0%
H: 2.28%
C: -2.27%
SNYNF | News | $108.84 |
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
BMY | $78.7 -1.6% 0.38% |
|
Health Technology
|
| O: 0.78%
H: 1.72%
C: 0.95%
SNY | News | $52.13 -0.89% 0.0% |
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
AZN | $65.94 -0.86% 0.21% |
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
immunotherapy report therapy cancer market
Cancer Gene Therapy Market to Grow at 10.1% through 2032, Amid High Adoption in Breast Cancer Treatment - Future Market Insights, Inc.
Published: 2022-06-27 (Crawled : 15:20) - prnewswire.com
CRNX | $17.74 -4.57% 0.0% |
|
Health Technology
|
| O: 0.66%
H: 1.22%
C: -5.83%
AZN | $65.94 -0.86% 0.21% |
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
ADAP S | $1.74 2.35% 5.88% |
|
Health Technology
|
| O: 1.85%
H: 6.67%
C: 3.03%
AZNCF | $127.2501 |
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
GSK | $43.35 -0.8% 0.19% |
|
Health Technology
|
| O: -0.16%
H: 0.61%
C: 0.18%
GLAXF | $21.99 |
|
Health Technology
|
| O: 0.47%
H: 3.73%
C: 3.73%
AMGN | $243.6 -0.51% 0.47% |
|
Health Technology
|
| O: -0.08%
H: 0.45%
C: -0.13%
treatment therapy cancer market
Valued to be $104.2 Million by 2026, Eye Health Supplements Slated for Robust Growth Worldwide
Published: 2022-06-27 (Crawled : 14:00) - prnewswire.com
PFE | News | $50.66 -2.35% 0.4% |
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
for health eye growth
Valued to be $12.9 Billion by 2026, Crohn`s Disease (CD) Therapy Slated for Robust Growth Worldwide
Published: 2022-06-27 (Crawled : 12:20) - prnewswire.com
JNJ | News | $176.94 -2.84% 0.18% |
|
Health Technology
|
| O: 0.78%
H: 0.94%
C: 0.26%
NVO | News | $108.3 -4.07% 2.17% |
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
CCXI | $25.08 -3.54% 0.0% |
|
Health Technology
|
| O: -4.88%
H: 1.04%
C: -1.25%
AZN | $65.94 -0.86% 0.21% |
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
AZNCF | $127.2501 |
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
PFE | News | $50.66 -2.35% 0.4% |
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
disease for therapy growth
Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights
Published: 2022-06-24 (Crawled : 18:00) - prnewswire.com
ALPMY | $15.95 |
|
Manufacturing
|
| O: 4.33%
H: 0.0%
C: -2.44%
ALPMF | $15.83 |
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -0.5%
ABBV | News | $152.49 -0.42% 0.0% |
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
BHC A | $8.83 1.73% 0.11% |
|
Health Technology
|
| O: 5.78%
H: 13.91%
C: 13.78%
IRWD | $11.54 -0.52% 0.0% |
|
Health Technology
|
| O: 0.27%
H: 2.08%
C: 1.99%
TAK | $13.86 -1.42% 0.0% |
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
treatment market
Psoriasis Treatment Market Players Observe Rising Trend of Personalized Medicines, According to TMR Report
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
AZN | $65.94 -0.86% 0.21% |
|
Health Technology
|
| O: 4.41%
H: 0.0%
C: 0.0%
JNJ | News | $176.94 -2.84% 0.18% |
|
Health Technology
|
| O: 1.94%
H: 0.0%
C: 0.0%
PFE | News | $50.66 -2.35% 0.4% |
|
Health Technology
|
| O: 2.96%
H: 0.0%
C: 0.0%
AZNCF | $127.2501 |
|
Health Technology
|
| O: 0.64%
H: 4.18%
C: 1.33%
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
LLY | News S | $317.62 -2.95% -0.03% |
|
Health Technology
|
| O: 3.32%
H: 0.0%
C: 0.0%
treatment report psoriasis market
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
Published: 2022-06-24 (Crawled : 12:00) - globenewswire.com
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
scemblix treatment for chmp novartis leukemia positive
Rheumatoid Arthritis Drugs Market Size to Grow by USD 14.90 Billion | 37% of the growth will originate from Europe | Technavio
Published: 2022-06-24 (Crawled : 09:00) - prnewswire.com
ALPMY | $15.95 |
|
Manufacturing
|
| O: 4.33%
H: 0.0%
C: -2.44%
SNY | News | $52.13 -0.89% 0.0% |
|
Health Technology
|
| O: 3.49%
H: 0.0%
C: 0.0%
ALPMF | $15.83 |
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -0.5%
ABBV | News | $152.49 -0.42% 0.0% |
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
GLAXF | $21.99 |
|
Health Technology
|
| O: 3.19%
H: 2.28%
C: -1.81%
AMGN | $243.6 -0.51% 0.47% |
|
Health Technology
|
| O: 0.92%
H: 0.82%
C: 0.56%
GSK | $43.35 -0.8% 0.19% |
|
Health Technology
|
| O: 1.79%
H: 0.95%
C: 0.92%
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
GLMD | $0.5756 10.69% 0.0% |
|
Health Technology
|
| O: 1.21%
H: 0.0%
C: -3.5%
europe growth market
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
Published: 2022-06-23 (Crawled : 01:00) - globenewswire.com
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
research disease novartis
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
Published: 2022-06-22 (Crawled : 00:00) - globenewswire.com
NVS | $84.17 -1.3% 0.17% |
|
Health Technology
|
| O: 0.3%
H: 0.0%
C: 0.0%
fda for novartis approval tafinlar
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistLast 48 Hours Insiders Buying
ALTG P 3227 | $9.29 -2.52% 0.0% |
|
Distribution Services
| 01:40
SKIL P 30000 | $3.61 -6.96% 0.0% |
|
Information
| 23:50
CAMP P 20000 | $4.65 -1.27% -0.43% |
|
Electronic Technology
| 16:00